World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
68
Citations
26293
World Ranking
2124
National Ranking
890

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Roy M. Gulick is a researcher affiliated with Cornell University in the United States with a focus on medicine, particularly within infectious diseases. Their work spans multiple subfields, including infectious diseases, virology, epidemiology, neurology, and emergency medicine.

The main topics of Roy M. Gulick's research encompass:

  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • HIV-related health complications and treatments
  • COVID-19 and healthcare impacts

Roy M. Gulick has contributed to numerous publications, with frequent appearances in the following venues:

  • UNC Libraries
  • Annals of Internal Medicine
  • Clinical Infectious Diseases
  • New England Journal of Medicine
  • AIDS and Behavior

Recent representative papers include:

  • "Clinical Characteristics of Covid-19 in New York City" (2020), New England Journal of Medicine
  • "Severe Covid-19" (2020), New England Journal of Medicine
  • "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women" (2021), New England Journal of Medicine
  • "COVID-19 in Hospitalized Adults With HIV" (2020), Open Forum Infectious Diseases
  • "Obesity and COVID-19 in New York City: A Retrospective Cohort Study" (2020), Annals of Internal Medicine

Collaborations form an important part of Roy M. Gulick's work, with frequent coauthors including:

  • Raphael J. Landovitz
  • Kenneth H. Mayer
  • Eric S. Daar
  • Marybeth McCauley
  • Mark A. Marzinke

Recognized by peers, Roy M. Gulick is a member of the Association of American Physicians, reflecting a standing within the medical community.

Best Publications

  • Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    R M Gulick;J W Mellors;D Havlir;J J Eron

  • Clinical Characteristics of Covid-19 in New York City.

    Parag Goyal;Justin J. Choi;Laura C. Pinheiro;Edward J. Schenck

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Severe Covid-19

    David A. Berlin;Roy M. Gulick;Fernando J. Martinez

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Marina Caskey;Florian Klein;Julio C. C. Lorenzi;Michael S. Seaman

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

    David W Haas;Heather J Ribaudo;Richard B Kim;Camlin Tierney

  • Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

    Roy M. Gulick;Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Stephanie Lustgarten

  • Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

    Patrice Severe;Marc Antoine Jean Juste;Alex Ambroise;Ludger Eliacin

  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression

    Pilar Mendoza;Henning Gruell;Lilian Nogueira;Joy A. Pai

  • HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

    Johannes F. Scheid;Johannes F. Scheid;Joshua A. Horwitz;Yotam Bar-On;Edward F. Kreider

  • Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Marina Caskey;Till Schoofs;Henning Gruell;Allison Settler

  • Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti

    Patrice Severe;Paul Leger;Macarthur Charles;Francine Noel

  • Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

    David B. Clifford;Scott Evans;Yijun Yang;Edward P. Acosta

  • Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

    Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  • ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

    Robert L. Murphy;Scott Brun;Charles Hicks;Joseph J. Eron

  • Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection: 100-Week Follow-up

    Roy M. Gulick;John W. Mellors;Diane Havlir;Joseph J. Eron

  • Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

    Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Christina Lalama

  • 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

    Roy M. Gulick;John W. Mellors;Diane Havlir;Joseph J. Eron

Frequent Co-Authors

Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Edward P. Acosta
Edward P. Acosta University of Alabama at Birmingham
David W. Haas
David W. Haas Vanderbilt University Medical Center
Richard Haubrich
Richard Haubrich University of California, San Diego
Charles Flexner
Charles Flexner Johns Hopkins University
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Robert L. Murphy
Robert L. Murphy Northwestern University
Susan A. Fiscus
Susan A. Fiscus University of North Carolina at Chapel Hill
Eric S. Daar
Eric S. Daar Lundquist Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to Microbiology can open diverse career paths, especially for students seeking flexible learning options. For those interested in public health, considering mph online programs with easy admission requirements is a smart way to advance without the stress of strict entry criteria.

Many graduates also explore allied health fields. For example, becoming a child.life specialist salary can be rewarding, combining science knowledge with emotional support skills.

Importantly, online education provides accessible opportunities for diverse populations, including those with past convictions. Programs highlighted under college degrees for felons demonstrate how higher education can be inclusive and supportive, allowing individuals to rebuild their careers.

For those interested in nursing and holistic health, functional medicine np programs offer specialized tracks that blend traditional microbiology with innovative patient care approaches.

Altogether, these pathways illustrate the versatility of microbiology foundations and the wide range of accessible online degrees that can lead to meaningful, well-paying careers.

Best Scientists Citing Roy M. Gulick

Trending Scientists

Recently Published Articles